Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the “Status of Cellular Therapy in the Asia Pacific Rim” Session ...
February 04 2019 - 8:15AM
Avalon GloboCare Corp. (NASDAQ: AVCO) (NASDAQ listed Avalon
GloboCare AVCO), a leading global developer of cell-based
technologies and therapeutics, announced today that its President
and Chief Executive Officer, David Jin, M.D., Ph.D., will co-chair
a session, entitled “Status of Cellular Therapy in the Asia Pacific
Rim,” at the Transplantation & Cellular Therapy (TCT) Meetings
in Houston, TX. TCT Meetings are the combined annual meetings of
the American Society of Blood and Marrow Transplantation (ASBMT)
and the Center for International Blood and Marrow Transplant
Research (CIBMTR).
|
|
Date: |
Saturday, February 23,
2019 |
Time: |
1:45PM - 2:30PM |
Location: |
Hilton Americas Houston
- Grand Ballroom G |
|
1600 Lamar Street,
Houston, Texas |
|
|
The session, "Status of Cellular Therapy in the
Asia Pacific Rim," will provide a venue to review and examine the
current status and future trends in cellular therapy (particularly
CAR-T), within Asia and the Pacific Rim region. Faculty for this
session will include speakers from China, Japan, and South Korea
and will discuss and exchange knowledge on clinical protocols,
outcome analysis, regulatory affairs, standardization, and
accreditation related to cellular therapy.
Additionally, Avalon GloboCare announces that it
has been accepted as a member of the Corporate Council of the
American Society for Blood and Marrow Transplantation
(ASBMT). Avalon joins a select group of twenty leading
biotech companies within the cellular therapy sector, including
Novartis, Merck and Co., Amgen, Gilead/Kite, Bristol-Myers
Squibb/Celgene, Sanofi Genzyme, Takeda Oncology and others.
Council members meet with ASBMT Board Members
and Past-Presidents to discuss critical BMT and cellular therapy
issues of mutual concern, find solutions to pressing challenges,
share knowledge on best practices and advise ASBMT on its major
initiatives. By pooling their resources and expertise, Council
members and the ASBMT Board can engage in joint problem-solving and
collaborative opportunities that will advance the cause and culture
of blood and marrow transplantation and cellular therapy.
“We are honored to lead this panel discussion at
the industry renowned TCT Meetings, comprising the leading experts
in an evolving cellular therapy ecosystem. We look forward to
leveraging our respective experience and capabilities in cell-based
technologies and therapeutics. We are also honored to join the
ASBMT’s Corporate Council in order to collaborate alongside many of
the world’s largest biotech companies. We will contribute our
scientific, regulatory, clinical and commercial expertise to help
empower high impact, transformative cell-based technologies and
their clinical applications,” stated David Jin, M.D., Ph.D., CEO
and President of Avalon GloboCare.
About Avalon GloboCare
Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global
intelligent biotech developer and healthcare service provider
dedicated to advancing cell-based technologies and therapeutics,
with a focus on developing and empowering innovative and
transformative cell-based technologies and their clinical
applications. In addition, Avalon provides strategic advisory
and outsourcing services to facilitate and enhance its clients'
growth, development, as well as competitiveness in both the
domestic and global healthcare markets. Through its
subsidiaries, namely GenExosome Technologies Inc. and Avactis
Biosciences Inc., Avalon is establishing a leading role in the
fields of exosome-based diagnostics, cellular immunotherapy
(including CAR-T/CAR-NK), and regenerative medicine.
Forward-Looking Statements Certain
statements contained in this press release may constitute
"forward-looking statements." Forward-looking statements
provide current expectations of future events based on certain
assumptions and include any statement that does not directly relate
to any historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors as disclosed in our
filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information: Avalon
GloboCare Corp. 4400 Route 9, Suite 3100 Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations: Crescendo
Communications, LLC Tel: (212) 671-1020 avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Apr 2023 to Apr 2024